The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. SVP, General Counsel Chan Henry Lee sold 1,115 American Depositary Shares at $375 per share on September 30, 2026, under a Rule 10b5-1 trading plan adopted on May 29, 2026. After the sale, his reported direct holding was 311,324 ordinary shares, including 507 acquired under the Company's 2018 Employee Share Purchase Plan. Each American Depositary Share represents 13 ordinary shares.
Xiaodong Wang, BeOne Medicines Ltd.’s Chair of the Scientific Advisory Board, exercised share options covering 403,364 Ordinary Shares at $2.84 per Ordinary Share on September 28, 2026, acquiring 31,028 American Depositary Shares (ADS); each ADS represents 13 Ordinary Shares. He reported sales of 31,028 ADS under a Rule 10b5-1 plan adopted June 9, 2026. He also reported direct holdings of 4,588,113 Ordinary Shares and options covering 806,715 Ordinary Shares after the transactions.
For BeOne Medicines Ltd. (ONC), officer Chan Lee reported a proposed sale of 1,115 ADS with an aggregate market value of $407,276.05; the approximate sale date is September 30, 2026, and Morgan Stanley Smith Barney LLC is listed as broker. The securities to be sold were acquired upon vesting of restricted stock units from July 29, 2022, through June 10, 2025. The past-three-month sales table lists four earlier transactions, three labeled as 10b5-1 sales and one in common shares.
BeOne Medicines Ltd. (ONC) received an amended Schedule 13D from investment entities affiliated with Baker Bros., updating their ownership and recent transactions in the company’s Ordinary Shares and ADS. Baker Bros. Advisors LP and Baker Bros. Advisors (GP) LLC each report beneficial ownership of 115,457,154 Ordinary Shares, representing 7.8% of the outstanding class. Julian C. Baker and Felix J. Baker each report beneficial ownership of 115,912,814 Ordinary Shares, also 7.8%, while FBB3 LLC reports 144,517 Ordinary Shares, or 0.01%.
The filing notes that on September 14, 2026, the adviser funded the exercise of Share Options held by employees Michael Goller and Ranjeev Krishana, resulting in the acquisition of 30,768 ADS (equivalent to 399,984 Ordinary Shares) at $36.83 per ADS, for total consideration of $1,133,185.44. These exercises were financed through draws of $94,095.86 on the 667 revolving note and $1,039,089.58 on the Life Sciences revolving note, each bearing interest at 5.12% per annum and due by May 1, 2053 or earlier upon sale of the ADS. The Baker entities state they hold their positions for investment purposes and may increase or decrease their holdings depending on various factors.
BeOne Medicines Ltd. (ONC) reported that entities associated with Baker Bros. Advisors LP exercised non-qualified share options previously granted to two employees for their past board service and received American Depositary Shares (ADS) on September 14, 2026. A total of 30,768 ADS were reported as received upon exercise of 15,384 share options issued to each of Ranjeev Krishana and Michael Goller at an exercise price of $36.83 per ADS. The funds managed by Baker Bros. Advisors LP have an indirect proportionate pecuniary interest in these ADS, while the employees and Felix J. Baker do not retain direct pecuniary interests in the compensation-related securities. Baker Bros. Advisors LP has voting and dispositive power over the options, RSUs and shares held for the benefit of the funds, and the Baker parties disclaim beneficial ownership except to the extent of their pecuniary interest.
BeOne Medicines Ltd. (ONC) director and Scientific Advisory Board chair Wang Xiaodong reported multiple equity transactions on September 8, 2026. He exercised options covering 403,351 Ordinary Shares at an exercise price of $2.84 per share, leaving options on 1,210,079 Ordinary Shares outstanding. On the same date, he acquired 31,027 American Depositary Shares (ADS) (each ADS representing 13 Ordinary Shares) through an exercise or conversion and sold a total of 38,287 ADS in a series of open-market transactions at weighted-average prices in the mid-$300s per ADS, executed under a Rule 10b5-1 trading plan adopted on June 9, 2026. Following these transactions, he directly held 4,588,113 Ordinary Shares and also had indirect interests through family-related entities and a family trust, for which he disclaims beneficial ownership.
BeOne Medicines Ltd. (ONC) received a notice that Xiaodong Wang, identified as a director and chair of its Scientific Advisory Board, plans to sell up to 131,370 ADS under Rule 144 through a broker on or after September 8, 2026.
The planned sale consists of 124,110 ADS to be received upon exercise of stock options over the next three months and 7,260 ADS acquired upon vesting of restricted stock units between June 22, 2022 and June 15, 2026. The aggregate market value of the ADS to be sold is stated as $47,064,616.20, with 57,914,782 ADS outstanding.
BeOne Medicines Ltd. (ONC) reported that Principal Accounting Officer Titus B. Ball sold 132 American Depositary Shares on September 1, 2026 at $355.86 per ADS. The sale was effected pursuant to a mandatory tax withholding provision tied to the vesting of a restricted share unit award. Each ADS represents 13 Ordinary Shares, and following this transaction he directly holds 97,929 Ordinary Shares. No Rule 10b5-1 trading plan is reported.
BeOne Medicines Ltd. (ONC) discloses that Titus Benjamin Ball plans to sell 132 American Depositary Shares (ADS) of the company under Rule 144, following restricted stock vesting under a registered plan. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ. Over the prior three months, Titus Benjamin Ball reported sales of 169 ADS on June 11, 2026 for $43,466.56 and 136 ADS on June 8, 2026 for $36,900.64.
BeOne Medicines Ltd. (ONC) officer Wu Xiaobin, President and COO, reported selling 280 American Depositary Shares (ADS) of BeOne Medicines on 2026-08-25 at $380.00 per ADS in an open-market or private transaction. Each ADS represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-11-07. After these transactions, Wu reported direct ownership of 1,270,084 Ordinary Shares and indirect ownership of 4,000 ADS held by his wife.